Targeted therapy prolongs life in patients with HER2-positive breast cancer
Friday, December 11, 2009 - 16:56
in Health & Medicine
SAN ANTONIO -- Lapatinib plus trastuzumab are significantly better than lapatinib alone in extending the lives of breast cancer patients whose tumors are HER2-positive, according to Kimberly Blackwell, M.D., associate professor of medicine at Duke University Medical Center. Blackwell presented the findings today at the CTRC-AACR San Antonio Breast Cancer Symposium. Link: http://www.dukemednews.org
Read the whole article on Science Blog
More from Science Blog
Related
- Targeted therapy prolongs life in patients with HER2-positive breast cancerFri, 11 Dec 2009, 13:59:03 EST
- Combination therapy reduced HER2-positive breast cancersFri, 10 Dec 2010, 10:05:57 EST
- Phase III study compared neoadjuvant therapy with lapatinib or trastuzumab for early breast cancerFri, 10 Dec 2010, 10:05:56 EST
- HER2 levels may aid in treatment selection for metastatic breast cancerTue, 2 Dec 2008, 10:49:47 EST
- Scientists developing new therapy for HER2-positive breast cancerTue, 26 Jul 2011, 17:35:00 EDT